AHA: Lilly, BI's Jardiance drops CV hospitalizations over rivals by Kyle Blankenship Sunday, November 17, 2019 In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.
AHA: AZ's Farxiga data show big benefit in non-diabetics by Kyle Blankenship Saturday, November 16, 2019 AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics look particularly strong.
Eli Lilly, Boehringer's SGLT2 med hits snag in Type 1 diabetes by Kyle Blankenship Thursday, November 14, 2019 Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.
Novo's Rybelsus still no bargain compared with Jardiance: ICER by Arlene Weintraub Friday, November 1, 2019 ICER concluded that Novo Nordisk's diabetes pill Rybelsus will be less cost-effective than Jardiance as an add-on therapy in type 2 diabetes.
AZ's Farxiga nabs first FDA cardiovascular nod by Kyle Blankenship Monday, October 21, 2019 AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.
Jardiance tops GLP-1s in real-world heart failure study by Carly Helfand Thursday, September 19, 2019 New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.
Lilly, BI tout new Jardiance kidney analysis as rival J&J nears by Carly Helfand Tuesday, September 17, 2019 Lilly and BI unveiled new Jardiance data that could line them up to compete with Johnson & Johnson's Invokana in a new patient group.
AstraZeneca's Farxiga nabs FDA fast track for CV outcomes use by Kyle Blankenship Monday, September 16, 2019 AstraZeneca is touting SGLT2 med Farxiga’s cardiovascular outcomes win as a game changer for the market. Turns out the FDA likes those results, too.
Oral semaglutide is not as cost-effective as Jardiance: ICER by Arlene Weintraub Thursday, September 12, 2019 Heart benefits offered by Novo Nordisk's oral version of its hit drug for Type 2 diabetes, Ozempic, won't justify its price, ICER said.
Armed with cardio data, AZ plans to pump up Farxiga promos by Kyle Blankenship Friday, September 6, 2019 Now that AstraZeneca has scored its Farxiga outcomes data, it's beefing up its sales team to prepare for an expanded FDA approval.